CLL1221
Safe Harbor Landing Pad Cell Line Jurkat T-Lymphocytes
human male peripheral blood (Source Disease: Acute T cell leukemia)
Synonym(s):
T-Lymphocyte Cell Line
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
41106514
NACRES:
NA.81
Recommended Products
product name
Safe Harbor Landing Pad Cell Line Jurkat T-Lymphocytes,
biological source
human male peripheral blood (Source Disease: Acute T cell leukemia)
Quality Level
form
frozen liquid (Vial of Frozen Cells)
growth mode
Suspension
technique(s)
cell culture | mammalian: suitable
shipped in
dry ice
storage temp.
−196°C
General description
The STR profile of this cell line matches that of its parental cell line ATCC® Catalog No. TIB-152. Jurkat T lymphocytes are a human, acute T cell lymphoma cell line isolated in the late 1970s from the peripheral blood of a young male patient suffering from T cell leukemia. The cells possess a pseudodiploid karyotype and have been characterized as expressing CD3 and, upon stimulation, interleukin-2.
Cell Line Description
These cells are a human, acute T cell lymphoma cell line isolated from the peripheral blood of a young male suffering from T cell leukemia. The cells possess a pseudodiploid karyotype, express CD3 and, upon stimulation, IL-2.
Application
This product is a human Jurkat T-lymphocyte cell line in which a landing pad cassette has been integrated into the AAVS1 safe harbor locus using CompoZr® Zinc Finger Nuclease technology. The mKATE2 fluorescence gene was integrated following the EF1a promoter and flanked by unique Cre-lox sites. The design of this landing pad cassette allows for easy, fast, and affordable genetic modification using Cre recombinase. mKATE2 can easily be exchanged for a payload of the user′s choice using Cre recombinase and a targeting vector with appropriate lox sites. Cells can then be sorted via fluorescence-activated cell sorting (FACS) for loss of mKATE2 expression as a surrogate for successful integration of the targeting vector. Approximately 7-10 days are required for loss of the mKATE2 signal in successfully targeted cells. See technical bulletin for detailed protocols.
Features and Benefits
These cells contain the mKATE2 fluorescence gene flanked by unique Cre-lox sites inserted in the AAVS1 safe harbor gene. These Jurkat cells are grown in suspension with a doubling time of approximately 22 hours.
Quality
Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, short terminal repeat (STR) analysis for cell line identification.
Culture Medium
RPMI modified to contain 2mM L-glutamine, 10mM HEPES, 1mM sodium pyruvate, and 1500mg/L sodium bicarbonate. Add 10% FBS(Catalog Number F2442).
Legal Information
ATCC is a registered trademark of American Type Culture Collection
CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Met. Corr. 1
Storage Class Code
8A - Combustible corrosive hazardous materials
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Kimi Araki et al.
Nucleic acids research, 30(19), e103-e103 (2002-10-05)
The Cre-lox system is an important tool for genetic manipulation. To promote integrative reactions, two strategies using mutant lox sites have been developed. One is the left element/right element (LE/RE)-mutant strategy and the other is the cassette exchange strategy using
Huseyin Tas et al.
PloS one, 10(9), e0136963-e0136963 (2015-09-04)
We describe an optimized system for the easy, effective, and precise modification of the Escherichia coli genome. Genome changes are introduced first through the integration of a 1.3 kbp Landing Pad consisting of a gene conferring resistance to tetracycline (tetA)
Zhong-Wei Du et al.
Stem cells (Dayton, Ohio), 27(5), 1032-1041 (2009-05-06)
To circumvent the silencing effect of transgene expression in human embryonic stem cells (hESCs), we employed the Cre recombination-mediated cassette exchange strategy to target the silencing-resistant site in the genome. We have identified new loci that sustain transgene expression during
Related Content
Fluorescently tagged cell lines for drug discovery, and high content imaging analysis; lung cancer knockout, breast cancer knockout, colorectal carcinoma knockout.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service